Autopsy report · NCT00405808
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Cause of deathRegulatory or ethics
“EMEA recommendation to suspend Acomplia marketing authorisation”
Life of this trial
- Ran for about 2 years 2 months before it stopped.
- 2,666 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Conditions
- Obesity
- Interventions
- Rimonabant; Placebo
- Participants
- 2,666
- Sites
- 27
- Countries
- Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Egypt, Finland, France, Greece, Hungary and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.